Ensysce Biosciences (ENSC) Non-Current Deferred Tax Liability (2018 - 2019)
Ensysce Biosciences (ENSC) posted quarterly Non-Current Deferred Tax Liability of $8920.0 for Q3 2019, down 31.46% quarter-over-quarter from $13014.0 in Q2 2019.
Ensysce Biosciences (ENSC) Non-Current Deferred Tax Liability (2018 - 2019) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Non-Current Deferred Tax Liability for 2 consecutive years, with $8920.0 the latest figure, recorded in Q3 2019.
- In Q3 2019, Non-Current Deferred Tax Liability changed N/A year-over-year to $8920.0; the TTM figure through Sep 2019 stood at $8920.0 (changed N/A YoY), while the FY2018 annual figure was $1764.0, changed N/A from the prior year.
- Non-Current Deferred Tax Liability fell to $8920.0 in Q3 2019 per ENSC's latest filing, from $13014.0 in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $13014.0 in Q2 2019 and bottomed at $1764.0 in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Ensysce Biosciences | 942,649.19 | -3.37 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 8,920.00 |
| Sep 30, 2019 | 8,920.00 |
| Jun 30, 2019 | 13,014.00 |
| Jun 30, 2019 | 13,014.00 |
| Dec 31, 2018 | 1,764.00 |
| Dec 31, 2018 | 1,764.00 |